|
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trails to clinical practice
|
Radioimmunotherapy (RIT) is a new treatment modality for B-- cell non-Hodgkin's lymphoma (NHL). Recent clinical trials have clearly established its efficacy in NHL patients refractory to standard chemotherapy or immunotherapy with the widely used unconjugated rituximab monoclonal antibody (mAb). The Food and Drug Administration has approved ^sup 90^Y-ibritumomab tiuxetan anti-B-cell NHL mAb as the first commercially available radiolabeled antibody for cancer therapy. This comes only a few yea...
Related newspaper, magazine, and journal articles from HighBeam Research
|
|
Clinical Experience with ¿-Particle-Emitting ^sup 211^At: Treatment of Recurrent Brain Tumor Patients with ^sup 211^At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6
The Journal of Nuclear Medicine
; α-Particle-emitting radionuclides, such as ^sup 211^At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity
|
|
|
Effects of Therapy with [^sup 177^Lu-DOTA^sup 0^, Tyr^sup 3^]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma
The Journal of Nuclear Medicine
; Therapy using the radiolabeled somatostatin analog [^sup 177^LuDOTA^sup 0^,Tyr^sup 3^]octreotate (^sup 177^Lu-octreotate) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N',NNtetraacetic acid) has been used primarily in gastroenteropancreatic neuroendocrine tumors. Here we present the effects of this
|
|
|
Treatment with ^sup 177^Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After Treatment with ^sup 90^Y-DOTATOC
The Journal of Nuclear Medicine
; Therapy with [^sup 90^Y-DOTA^sup 0^, Tyr^sup 3octreotide (DOTATOC, where DOTA = tetraazacyclododecane tetraacetic acid and TOC = D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) is established for the treatment of metastatic neuroendocrine tumors. Nevertheless, many patients experience disease relapse,
|
|
|
^sup 68^Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with ^sup 18^F-FDG
The Journal of Nuclear Medicine
; Dynamic PET stuthes with a ^sup 68^Ga-bombesin analog, DOTA-PEG^sub 2D-Tyr^sup 6^, β-Ala^sup 11^,Thi^sup 13^,Nle^sup 14^] BN(6-14) amide (^sup 68^Ga-BZH^sub 3^; DOTA is 1,4,7,10-tetraazacyclododecane-N,N',NNtetraacetic acid, and PEG is ethylene glycol [2-aminoethyl-carboxymethyl ether were
|
|
|
Biologic Dosimetry of ^sup 188^Re-HDD/Lipiodol Versus ^sup 131^I-Lipiodol Therapy in Patients with Hepatocellular Carcinoma
The Journal of Nuclear Medicine
; One approach to treatment of primary hepatocellular carcinoma (HCC) is intraarterial injection of ^sup 131^I-lipiodol. Although clinical results have been positive, the therapy can be improved by using ^sup 188^Re instead of ^sup 131^I as the radionuclide. ^sup 188^Re is a highenergy
|
|
|
Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with ^sup 131^I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results
The Journal of Nuclear Medicine
; Results from animal experiments have shown that human lgG2/ mouse chimeric antitenascin 81C6 (ch81C6) monoclonal antibody exhibited higher tumor accumulation and enhanced stability compared with its murine parent. Our objective was to determine the effect of these differences on the maximum
|
|
|
Combined Use of ^sup 99m^Tc-Sestamibi and ^sup 99m^Tc-V-DMSA in the Assessment of Chemotherapy Effectiveness in Patients with Multiple Myeloma
The Journal of Nuclear Medicine
; This study determined the role of the combined use of ^sup 99m^Tc-sestamibi and ^sup 99m^Tc-pentavalent dimercaptosuccinic acid (V-DMSA) scintigraphy in evaluating the effectiveness of chemotherapy in patients with multiple myeloma. Methods: In 20 patients with multiple myeloma who had received or
|
|
|
Exploratory Study of ^sup 99m^Tc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors
The Journal of Nuclear Medicine
; ^sup 99m^Tc-EC20 is a folate receptor (FR)-targeted imaging agent consisting of the vitamin folate conjugated to ^sup 99m^Tc. FR is expressed on a variety of epithelial cancers, with advanced cancers often expressing FR at significantly higher levels than earlier stages of the disease. The goals of
|
|
|
Tumor Localization of 16[beta]-^sup 18^F-Fluoro-5[alpha]-Dihydrotestosterone Versus ^sup 18^F-FDG in Patients with Progressive, Metastatic Prostate Cancer
The Journal of Nuclear Medicine
; This trial was an initial assessment of the feasibility, in vivo targeting, and biokinetics of 16[betasup 18^F-fluoro-5[alpha]-dihydrotestosterone (^sup 18^F-FDHT) PET in patients with metastatic prostate cancer to assess androgen receptor expression. Methods: Seven patients with progressive
|
|
|
Gluc-Lys([^sup 18^F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [^sup 111^In]DTPA-Octreotide
The Journal of Nuclear Medicine
; A recently developed ^sup 18^F-labeled PET tracer for somatostatin receptor (sstr) imaging, N^sup α1-deoxy-D-fructosyl)-N^sup ε2sup 18^F]fluoropropionyl)-Lys^sup 0^-Tyr^sup 3^-octreotate (Gluc-Lyssup 18^F]FP)-TOCA), was evaluated in patients with sstr-positive tumors by assessing the
|